RECOVER: Phase 2 Randomized, Double-Blind Trial TREating Hospitalized Patients With COVID-19 With Camostat MesilatE, a TMPRSS2 Inhibitor
RCT 100 patients showing no significant difference with camostat. Results are currently unclear—different mortality numbers were provided for all-cause mortality and mortality rate (2/50 vs. 3/46 for the treatment group at 28 days, with the 28 day all-cause mortality result removed in an updated submission). The main outcome measures appear to be different due to only including patients that submitted day 28 outcome data.
Standard of Care (SOC): SOC for COVID-19 in the study country,
the USA, is
very poor with
very low average efficacy for approved treatments
1.
Only expensive, high-profit treatments were approved. Low-cost treatments were excluded, reducing the probability of treatment—especially early—due to access and cost barriers, and eliminating complementary and synergistic benefits seen with many low-cost treatments.
|
risk of death, 25.0% lower, RR 0.75, p = 1.00, treatment 3 of 50 (6.0%), control 4 of 50 (8.0%), NNT 50, day 56.
|
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Bryce et al., 28 Mar 2024, Double Blind Randomized Controlled Trial, placebo-controlled, USA, preprint, 1 author, trial
NCT04470544 (history) (RECOVER).
Contact: Nguyen.Vy@mayo.edu, ClinicalResearch@tmcaz.com, Vimoktayon.Torsak@mayo.edu, Pecenka.Stacey@mayo.edu.
